Atlas Trials

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Clinical trial NCT05318937 · COMPLETED

Trial details

NCT number
NCT05318937
Sponsor
Supernus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Parkinson DiseaseCognitive Dysfunction
Start date
2022-06-06
Primary completion
2024-01-17
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.